THALES
1.7.2021 09:02:13 CEST | Business Wire | Press release
As airports prepare for the busy summer period, they are facing a new set of challenges; dealing with the public health crisis and complying with new regulations on freedom of movement within the Schengen Area. Thales technologies enable airport operators, airlines and border officials to enhance the travel experience and increase security at four main points around the airport.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005080/en/
Secure check-in
Passengers can check in remotely from any location (home, hotel, etc.) using their airline's mobile app. The identity of each individual can then be instantly verified with face recognition
software, using a combination of a selfie taken by the passenger, liveness detection and a document authenticity check. The face recognition solution checks approximately 40 points on the passenger's face and issues an alert if there is any doubt about their identity.
Based on this identity verification and facial biometrics, a temporary digital token is then created for each passenger. The passenger's face then identifies them at check-in, bag drop-off, security, passport control and the boarding gate, removing the need to show a ticket and ID card at each checkpoint. The system analyses the facial features of an individual in real time, even when they are wearing a surgical mask, and matches it to the corresponding digital identity in the system. No personal data or photos are stored; an encrypted code created during check-in is the only reference the system requires.
Passengers are identified at the boarding gate in less than a second
During boarding, passengers are instantly identified by face recognition, without needing to remove their masks or show their boarding passes. In some cases, ground staff may be required to ask a passenger to show their health pass, which can be stored in a digital ID wallet
on their smartphone, to prove their vaccination status, PCR test results, etc. This mobile ID wallet protects the passengers' personal data and certifies the authenticity, validity and integrity of the health data. Health passes can also be authenticated when passengers check in before arriving at the airport.
This biometric solution for boarding gates reduces boarding times by one-third. The system erases the temporary token once the aircraft has taken off.
Smart airport operations to optimise the flow of passengers
High-tech solutions from Thales also help to manage airport operations at numerous destinations. The Group provides airport operators with smart solutions and decision support tools that help them optimise and control passenger flows inside the terminal (from the entrance to the boarding and/or arrival gate). Using high-performance algorithms, these tools and solutions enable airport operators and other stakeholders to model flight arrivals and departures as well as other airport data and run simulations. Based on those simulations, they can anticipate possible travel disruptions (late or cancelled flights) and adjust resource availability on the ground to improve the passenger experience and reduce waiting times.
New border kiosks to simplify passport control for non-European nationals
Under the new requirements for member states of the Schengen Area, non-European nationals arriving in France will soon be able to use Thales's self-service border kiosks
to pre-register their identity, including their biometric data (fingerprint and facial biometrics), in less than one minute.
Pre-registration offers time savings of 30% at passport control. The system software is optimised for ultra-rapid document authentication and fraud detection. Several ports of entry (airports, ports, train stations) are due to be equipped with Thales’ border kiosks between now and May 2022.
"For several decades, Thales has been helping to manage and secure sensitive infrastructure like stations, sports arenas and other major cultural venues. With its expertise in new technologies such as AI, deep learning and biometrics, boosted by the acquisition of Gemalto in 2019, Thales is in a position to provide airports and their ecosystems with new ways to increase operational efficiency, better protect the health and safety of passengers and enhance the travel experience. Thales technologies offer secure solutions that simplify the passenger experience while guaranteeing that personal data is protected and managed with complete transparency." Philippe Keryer, Executive Vice President, Strategy, Research and Technology, Thales
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defence, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005080/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
